All In MedTech

Device Trial Radar · NCT03366155

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Jun 24, 2019

Primary completion

Nov 13, 2025

Study completion Nov 13, 2025

Sponsor

Sponsor type
NIH
First posted
Dec 8, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective. A device that does this a pump that delivers drugs over 2 weeks at constant rate into the hepatic artery. The person's body temperature causes the drug to flow from the pump. Researchers want to see if this helps people with colorectal metastases to the liver. Objective: To study the effectiveness of a hepatic artery infusion pump at treating colorectal metastases to the liver. Eligibility: Adults at least 18 years old with colorectal metastases to the liver Design: Participants will be screened with: Medical history Physical exam Heart, blood, and urine tests Scans Participants will stay in the hospital a few days. A small plastic tube (catheter) will be inserted in an artery into the liver. The catheter will be attached to the pump. That will lie under the skin on the abdomen. It will be small and participants will be able to feel it. Participants will get treatment in 28-day cycles. Every Day 1, they will have physical exam, symptom review, and blood tests. Every 2 weeks, they will come to the clinic to get chemotherapy by a catheter or port. Every 12 weeks, they will have a scan. Tissue samples may be taken during the study. When they finish the drug, participants may have the pump removed. They will repeat the Day 1 tests. They will be called every 6 months to see how they are doing.

Conditions

  • Colorectal Cancer
  • Liver Metastases
  • Colorectal Adenocarcinoma
  • Colorectal Cancer With Hepatic Metastases
  • Colorectal Carcinoma

Interventions

  • Codman 3000 constant flow pump catheterDevice

    Implanted Medtronic SynchroMed II Pump with codman 3000 Constant Flow Pump Catheter

  • PanitumumabDrug

    6 mg/kg, intravenous (IV)

  • FUDR-DexDrug

    Hepatic Artery Infusion Pump (HAIP) will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate), Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)

  • OxaliplatinDrug

    85 mg/m\^2, intravenous (IV)

  • 5FUDrug

    2000 mg/m\^2, intravenous (IV) 46-hour infusion of 5-Fluorouracil + 400 mg/m\^2, IV of Leucovorin

  • IrinotecanDrug

    150 mg/m\^2, intravenous (IV)

  • HAIP installationProcedure

    Hepatic Artery Infusion (HAI) pump installation

  • cetuximabDrug

    500 mg/m\^2, intravenous (IV)

  • Medtronic SynchroMed II PumpDevice

    Implanted Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter

  • FloxuridineDrug

    Floxuridine 0.12 mg/kg X pump volume X pump flow rate

  • DexamethasoneDrug

    1 mg/day X pump volume (30) X pump flow rate

  • EKGDiagnostic test

    Screening and baseline.

  • CT C/A/PDiagnostic test

    Screening, baseline and Cycle 1. One cycle is 28 (+/- 2 days).

  • CT Angiogram (abdomen)Diagnostic test

    Screening

  • Tumor and normal liver biopsyProcedure

    For research: During surgery to install pump, time of progression per principal investigator discretion if safe, and end of treatment.

  • LeucovorinDrug

    400 mg/m\^2, intravenous (IV), (Day15, Day1)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response Rate (RR) Reported With an 80% Confidence IntervalTime frame: 6 months
  2. Response Rate (RR) Reported With a 95% Confidence IntervalTime frame: 6 months
  3. Number of Grade 1, 2, 3, 4, and/or 5 Serious and/or Non-serious Adverse Events Reported With Type and FrequencyTime frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.